FiberSense adds automated sensor filling line in Germany

FiberSense AG has completed the first filling of sensor fibers on a new automated production line in Großostheim, Germany, a step the company says moves it closer to scalable series production. The upgrade supports the planned launch of its CE-marked CGM system in Q1 2027 and a wider portfolio of metabolic monitoring products.

Why it matters: - FiberSense’s new automated filling line is a manufacturing step toward reproducible, scalable series production. - The capability is meant to support both the company’s first diabetes-care product and future applications built on the same sensing platform. - The move signals that FiberSense is shifting from product development toward industrial-scale production.

What happened: - FiberSense AG completed the first filling of sensor fibers on its new automated filling line in Großostheim, Germany. - The company framed the milestone as part of its transition to series production. - Chairman and CEO Michael Tillmann called the step important as FiberSense prepares for its next stage of growth.

The details: - The new production setup automates a key step in making FiberSense’s high-tech biosensors. - FiberSense’s sensing platform uses proprietary photometric technology. - The platform is intended to anchor a broader continuous metabolic monitoring portfolio. - Dario Clos, who led implementation of the filling line, said the manufacturing base in Germany is designed to translate the technology into scalable products and support future growth. - FiberSense founder and CTO Dr. Achim Müller said the same industrialization capabilities will support the FiberSense CGM system for diabetes care and future applications based on the sensing platform. - The CE-marked FiberSense CGM system combines a 28-day wear cycle with a reusable detector. - FiberSense plans to launch the CGM system in Q1 2027. - The company also said a dedicated lifestyle offering is planned for launch next month. - FiberSense said the broader portfolio will cover medical, lifestyle and professional care applications. - More information is available in the company’s announcement and on its social profile.

Between the lines: - The new line suggests FiberSense is investing early in manufacturing infrastructure, not just product design. - That matters because biosensor businesses often need reliable, repeatable production before they can scale commercial supply. - The company is also signaling a multi-product strategy under its FiberSense CxM umbrella.

What's next: - FiberSense is preparing the launch of its dedicated lifestyle product next month. - The company is also moving toward the Q1 2027 launch of its CGM system. - Further product lines and applications are already in development under the broader monitoring portfolio.

The bottom line: - FiberSense is using manufacturing automation to turn its sensing platform into a scalable product family, with first commercial launches now on the near-term horizon.